Big news in exon skipping therapy today! BioMarin announced this morning that the FDA has accepted their New Drug Application (NDA) for drisapersen and Sarepta announced that they have completed their NDA submission for eteplirsen.
We are such a fortunate…
ContinueAdded by PPMD on June 29, 2015 at 10:34am — No Comments
On June 3, 2015, Dr. Michael Binks, Vice President for Rare Disease Clinical Research at Pfizer, presented information about the upcoming clinical trial of PF-06252616. The webinar provides an overview of Pfizer’s approach to advancing the science of an anti-myostatin monoclonal antibody as an investigational compound for potential therapeutic use in muscle wasting diseases, such as Duchenne muscular dystrophy. Dr. Binks gives a presentation and answers submitted…
ContinueAdded by PPMD on June 25, 2015 at 3:30pm — No Comments
Parent Project Muscular Dystrophy is excited to name Duke Children’s Hospital & Health Center (Duke Children’s) a Certified Duchenne Care Center. Duke…
ContinueAdded by PPMD on June 12, 2015 at 9:29am — No Comments
Today, we are blessed with an overwhelming number of industry and corporate partners who have committed themselves to the fight to end Duchenne. This kind of commitment was unheard of when PPMD started 21 years ago. Because of the dedication of these companies and others, we are stronger as a community. We are closer to ending Duchenne.…
ContinueAdded by PPMD on June 11, 2015 at 10:30am — No Comments
One of our most exciting and fast-growing programs at PPMD's Connect Conference is our Kids Track! This year, we will be expanding our…
Added by PPMD on June 4, 2015 at 12:30pm — No Comments
2018
2017
2016
2015
2014
2013
2012
2011
2010
© 2022 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service